pharm endo 2/3

description:

GH antagonists block the action of GH
drugs:

Pegvisomant (Somavert)
indication
- Acromegaly·
- MC cause: Benign GH (hyper)secreting pituitary adenoma
- For patients with persistently elevated IGF-1 despite other therapy
- May be monotherapy option
dose of pegvisomant is based on:

serum IGF-1 conc
kinetics:
- The addition of PEG-500 to GH ·
- Increases its half-life from 30 minutes to about 2 days
- As a protein·
- It cannot be taken orally
- Injected subcutaneously
CI

severe liver disease
SE:
- elevated liver enzymes (transaminases)
- 25% of pts
adverse effects:
- Central nervous system: ·
- Pain (8% to 14%)
- Gastrointestinal: ·
- Diarrhea (≤14%)·
- Nausea (≤14%)
- Local:
- Injection site reaction (4% to 11%)
- Miscellaneous: ·
- Infection (≤23%)·
- Flu-like syndrome (4% to 12%)
somatostatin:

Normalizes IGF-1 levels in about 65% of patients
Pegvisomant:
- Normalized IGF-1 levels in 97% of patients
- Reduced insulin and resting glucose levels but not HbA1c
- Doubled GH levels

Author

merazar15

230936

Card Set

pharm endo 2/3

Description

pharm endo 2/3, growth hormone antagonists

Updated

2013-08-22T20:29:34Z

Show Answers